医学診断法ジャーナル
オープンアクセス

概要

A systematic review of the prevalence and diagnostic studies of PIK3CA mutations in HR + / HER2 - metastatic breast cancer

Gloria Simmons

PIK3CA change recurrence differs among breast malignant growth (BC) subtypes. Ongoing proof proposes mix treatment with the PI3K inhibitor (PI3Ki) alpelisib and endocrine treatment (ET) improves reaction rates and movement free endurance (PFS) in PIK3CA- freak, chemical receptor positive (HR+) BC versus ET alone; hence, better understanding the clinical and epidemiologic components of these changes is justified. This methodical survey portrays the PIK3CA change the study of disease transmission, sort of testing draws near (e.g., fluid or tissue tumor biopsy), and soundness/concordance (e.g., consistency in outcomes by fluid versus strong tumor test, by a similar strategy over the long run) in patients with HR+/HER2–progressed (locally unresectable) or metastatic illness (HR+/HER2–mBC) and investigates execution (e.g., pairwise concordance, affectability, particularity, or prescient worth) of individual transformation discoveries. An exhaustive inquiry of PubMed/MEDLINE, EMBASE, Cochrane Central, and select gathering abstracts (i.e., AACR, ASCO, SABCS, ECCO, and ESMO meetings somewhere in the range of 2014 and 2017) distinguished 39 investigations of patients with HR+, HER2–mBC. The middle commonness of PIK3CA change was 36% (territory: 13.3% to 61.5%); distinguished testing approaches all the more generally utilized tissue over fluid biopsies and fundamentally used cutting edge sequencing (NGS), polymerase chain response (PCR), or Sanger sequencing.

There was concordance and strength between tissues (range: 70.4% to 94%) in light of restricted information. Given the clinical advantage of the PI3Ki alpelisib in patients with PIK3CA freak HR+/HER2–mBC, assurance of tumor PIK3CA transformation status is of significance in overseeing patients with HR+/HER2–mBC. Pervasiveness of this change and utility of test approaches probably warrants PIK3CA transformation testing in all patients with this bosom disease subtype by means of authoritative evaluation of PIK3CA mutational status.